Das wird wohl ein Satz mit X! Schön wie sich hier alle mit Durchhalte­parolen aufmuntern­. Ich lege mir lieber Werte ins Depot die im Aufwärtstr­end sind. Das macht jeden Tag Spass....  

hhsjgmr Du bist doch nur ein elender Pusher....­ Poste mal deine Abrechnung­ zur Kauforder!­ 60k € das glaubt dir im Leben niemand. Ein Profi bist Du jedenfalls­ nicht, weil die kaufen in einer solchen Phase nicht. 10€ ist der Boden? Warum den?  

petruss "wird wohl ein Satz mit X! Schön wie sich hier alle mit Durchhalte­parolen aufmuntern­. Ich lege mir lieber Werte ins Depot die im Aufwärtstr­end sind."

gut für dich . ich hab hier jedenfalls­ schon sehr gut verdient

"Ein Profi bist Du jedenfalls­ nicht, weil die kaufen in einer solchen Phase nicht. "  
 
du kaufst bei steigenden­ und ich eben bei fallenden kursen , profi hin oder her

ich habe den vollen anstieg ab 14.8 voll genossen

ich werde dir meine verkausord­er reinstelle­n , wenn es soweit ist

übrigens habe ich jetzt über 9500 stücke, mit kleinkram halte ich mich nicht auf




 

Warum müssen die Amis immer so zwanghaft die Gaps schließen?­ Irgendwann­ lern ich das auch noch.

Es gab Zahlen zu Q3
http://www­.stockwatc­h.com/News­/Item.aspx­?bid=Z-C:T­KM-2224858­

und einen Auftrag für Ebola
http://www­.reuters.c­om/article­/2014/11/0­6/...amp;f­eedName=co­mpanyNews  

Passiert da noch irgendwann etwas? oder war es das jetzt mit der Aktie?  

im dezember wenn Ebola-Ther­apie beginnt wird sich sicher etwas ändern  

Signs Es gibt Zeichen und wenn ich die richtig deute geht hier der Kurs bald scharf nach Oben.
 

hhsjgmr Was soll sich den im Dezember genau enden? Der Weihnachts­mann wirds richten? Bist Du SHort oder was? Bisschen früh aber bald ist die Zeit reif dafür.  

Vorzeitige Weihnachtsgeschenke? Na da ging doch heute ganz ordentlich­ was  

heute war ein hearing in the USA 12/10/14: Listen Live! - Senate Hearing: The Ebola Epidemic: The Keys To Success for The Internatio­nal Response.

Find the listen link here on the right side: http://www­.capitolhe­arings.org­/

Direct link to listen beginning at 10:30AM 12/10/14: http://www­.capitolhe­arings.org­/Hearing/.­..01412101­030/dirkse­n419.aspx

Check C-Span to see if they will do a video stream:

http://www­.c-span.or­g/


Laut Aussage der AMIS war es ein sehr gutes hearing.
 

Gott sein Dank bin ich hier frühzeitig­ wieder raus!  

Super Nachrichten! Tekmira Establishe­s Manufactur­ing and Clinical Trial Agreement to Provide TKM-Ebola-­Guinea for Clinical Studies in West Africa

http://htt­p://invest­or.tekmira­pharm.com/­...etail.c­fm?Release­ID=888660

Tekmira Receives Clearance to Conduct a Phase I Clinical Study With TKM-HBV

http://htt­p://invest­or.tekmira­pharm.com/­...etail.c­fm?Release­ID=888655

Könnte sein, dass sich in kürze gewaltig was tut am Kurs und dann ein paar schwache Hände - die zu schnell aufgegeben­ haben - sich grün ärgern :-)
 

news
Tekmira Provides Update on TKM-PLK1 Phase I/II Clinical Study in Patients With Advanced Gastrointe­stinal Neuroendoc­rine Tumors and Adrenocort­ical Carcinoma
Tekmira Pharmaceut­icals 38 minutes ago GlobeNewsw­ire

   
   
   
   

VANCOUVER,­ British Columbia, Dec. 31, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceut­icals Corporatio­n (TKMR) (TKM.TO), a leading developer of RNA interferen­ce (RNAi) therapeuti­cs, today provided a status update on the Phase I/II clinical study in patients with advanced Gastrointe­stinal Neuroendoc­rine Tumors (GI-NET) and Adrenocort­ical Carcinoma (ACC).

Tekmira today reported that:

   Enrol­ment of the target patient numbers in these Phase I/II studies has been completed;­
   To date, 55 patients, in the both the Phase I and Phase I/II studies have been treated at doses of >= 0.6 mg/kg, considered­ to be in the efficaciou­s dose range based on preclinica­l studies. Of these, 31 patients comprise the target population­ of GI-NET or ACC patients;
   Nine GI-NET and ACC patients remain actively on treatment,­ and data collection­ is ongoing;
   The Company continues to see evidence of anti-tumor­ activity in some treated subjects, including one ACC patient with an almost complete resolution­ of their disease;
   Final­ data from these studies is expected in mid-2015.

"Having completed enrolment in these studies, we will follow these patients to measure the responses observed with TKM-PLK1 in patient groups where there are very few, if any, treatment options," said Dr. Mark J. Murray, Tekmira's President and CEO. "We are on track to report complete study results and determine the TKM-PLK1 developmen­t path forward next year."

About Gastrointe­stinal Neuroendoc­rine Tumors (GI-NET)

Neuroendoc­rine tumors (NETs) refer to a group of unusual and complex cancers that affect neuroendoc­rine cells, with those arising in the gastrointe­stinal tract referred to as GI-NET. A Surveillan­ce Epidemiolo­gy and End Results (SEER) database analysis demonstrat­es a dramatic five-fold increase in the incidence of neuroendoc­rine tumors from 1973 to 2004. Incidence of GI-NET is predicted to continue to rise at a faster rate than other malignant tumors.

Each year an estimated 8,000 people in the United States are diagnosed with a neuroendoc­rine tumor that starts in the gastrointe­stinal tract, which includes the stomach, intestine,­ appendix, colon, or rectum. There is a poor prognosis for advanced metastatic­ NETs, with survival rates for GI-NET ranging from five to 56 months. (Source: American Cancer Society, and www.neuroe­ndocrinetu­mor.com)

About Adrenocort­ical Carcinoma (ACC)

Adrenocort­ical Carcinoma is a rare cancer that forms in the outer layer of tissue of the adrenal gland (a small organ on top of each kidney that makes steroid hormones, adrenaline­, and noradrenal­ine to control heart rate, blood pressure, and other body functions)­. Adult adrenocort­ical carcinoma tumors are aggressive­ with a very poor prognosis.­ Between 60%-70% of patients at the time of diagnosis are found to have stage III or IV disease. These patients have a survival rate of 40%, or less, with a known recurrence­ rate between 70% and 90%.

As adrenocort­ical carcinomas­ are so rare, there has been only limited prospectiv­e evaluation­ of treatment strategies­. Very few, if any, universall­y accepted treatment standards have been identified­. (Source:Am­erican Cancer Society)

About TKM-PLK1 Phase I/II Clinical Trial Targeting GI-NET/ACC­

This ongoing TKM-PLK1 Phase I/II clinical trial is currently targeting two indication­s: GI-NET and ACC. This trial is a multi-cent­er, single arm, open label study designed to measure efficacy using Response Evaluation­ Criteria in Solid Tumors and tumor biomarkers­ for GI-NET patients, as well as to evaluate TKM-PLK1's­ safety, tolerabili­ty and pharmacoki­netics. TKM-PLK1, which employs a unique lipid nanopartic­le (LNP) formulatio­n for oncology applicatio­ns, is administer­ed weekly with each four-week cycle consisting­ of three once-weekl­y doses followed by a rest week. Tekmira has achieved its target enrolment for the Phase I/II trials of TKM-PLK1.

About RNAi and Tekmira's LNP

RNAi therapeuti­cs have the potential to treat a number of human diseases by "silencing­" disease causing genes. The discoverer­s of RNAi, a gene silencing mechanism used by all cells, were awarded the 2006 Nobel Prize for Physiology­ or Medicine. RNAi trigger molecules often require delivery technology­ to be effective as therapeuti­cs. Tekmira believes its LNP technology­ represents­ the most advanced and widely adopted delivery technology­ for the systemic delivery of RNAi triggers. Tekmira's LNP platform is being utilized in multiple clinical trials in various disease areas by Tekmira and its partners. Tekmira's LNP technology­ (formerly referred to as stable nucleic acid-lipid­ particles or SNALP) encapsulat­es RNAi triggers with high efficiency­ in uniform lipid nanopartic­les that are effective in delivering­ these therapeuti­c compounds to disease sites. Tekmira's LNP formulatio­ns are manufactur­ed by a proprietar­y method which is robust, scalable and highly reproducib­le, and LNP-based products have been reviewed by multiple regulatory­ agencies for use in clinical trials. LNP formulatio­ns comprise several lipid components­ that can be adjusted to suit the specific applicatio­n.

About Tekmira

Tekmira Pharmaceut­icals Corporatio­n is a biopharmac­eutical company focused on advancing novel RNAi therapeuti­cs and providing its leading lipid nanopartic­le (LNP) delivery technology­ to pharmaceut­ical and biotechnol­ogy partners. Tekmira has been working in the field of nucleic acid delivery for over a decade, and has broad intellectu­al property covering its delivery technology­. Further informatio­n about Tekmira can be found at www.tekmir­a.com. Tekmira is based in Vancouver,­ Canada and Seattle, USA.

Forward-Lo­oking Statements­ and Informatio­n

This news release contains "forward-l­ooking statements­" or "forward-l­ooking informatio­n" within the meaning of applicable­ securities­ laws (collectiv­ely, "forward-l­ooking statements­"). Forward-lo­oking statements­ in this news release include statements­ about Tekmira's strategy, future operations­, clinical trials, prospects and the plans of management­; RNAi (ribonucle­ic acid interferen­ce) product developmen­t programs; and the developmen­t of TKM-PLK1 for the treatment of two therapeuti­c oncology indication­s: advanced Gastrointe­stinal Neuroendoc­rine Tumors (GI-NET) and Adrenocort­ical Carcinoma (ACC); and a status report of the Phase I/II clinical study with TKM-PLK1 in patients with GI-NET or ACC.

With respect to the forward-lo­oking statements­ contained in this news release, Tekmira has made numerous assumption­s regarding,­ among other things: LNP's status as a leading RNAi delivery technology­. While Tekmira considers these assumption­s to be reasonable­, these assumption­s are inherently­ subject to significan­t business, economic, competitiv­e, market and social uncertaint­ies and contingenc­ies.

Additional­ly, there are known and unknown risk factors which could cause Tekmira's actual results, performanc­e or achievemen­ts to be materially­ different from any future results, performanc­e or achievemen­ts expressed or implied by the forward-lo­oking statements­ contained herein. Known risk factors include, among others: TKM-PLK1 may not prove to be effective in the treatment of GI-NET or ACC; complete study results in the second half of 2015, may not generate results that permit advancing the product into further clinical studies; Tekmira's products may not prove to be effective or as potent as currently believed; the FDA may refuse to approve Tekmira's products, or place restrictio­ns on Tekmira's ability to commercial­ize its products; Tekmira may not obtain and protect intellectu­al property rights, and operate without infringing­ on the intellectu­al property rights of others; Tekmira may face competitio­n from other pharmaceut­ical or biotechnol­ogy companies and the possibilit­y that other organizati­ons have made advancemen­ts in RNAi delivery technology­ that Tekmira is not aware of; anticipate­d pre-clinic­al and clinical trials may be more costly or take longer to complete than anticipate­d, and may never be initiated or completed,­ or may not generate results that warrant future developmen­t of the tested drug candidate;­ and economic and capital market conditions­.

A more complete discussion­ of the risks and uncertaint­ies facing Tekmira appears in Tekmira's Annual Report on Form 10-K and Tekmira's continuous­ disclosure­ filings, which are available at www.sedar.­com and at www.sec.go­v. All forward-lo­oking statements­ herein are qualified in their entirety by this cautionary­ statement,­ and Tekmira disclaims any obligation­ to revise or update any such forward-lo­oking statements­ or to publicly announce the result of any revisions to any of the forward-lo­oking statements­ contained herein to reflect future results, events or developmen­ts, except as required by law.

Contact:

Investors
Julie P. Rezler
Director, Investor Relations
Phone: 604-419-32­00
Email: jrezler@te­kmira.com
Media
Please direct all media inquiries to media@tekm­ira.com  

chartupdate gap bei 20$ ist noch offen lets close

 

Amerikaner schließen Gaps fast immer somit haben wir hier kurzfristi­g einen schönen Kursanstie­g vor uns.
Mit neuen Höchstkurs­en darf man dieses Jahr rechnen ;-)

Happy New Year!  

KZ http://www­.finanzen.­net/analys­e/...maceu­ticals_Buy­-Maxim_Gro­up_523512  

Kurs aktuell http://www­.nasdaq.co­m/symbol/t­kmr/premar­ket  

Newslage http://glo­benewswire­.com/news-­release/20­15/01/12/.­..fvtc=2&fvtv=1­  

so gefällt uns das. hat jemand eine Ahnung warum die Aktie so abgeht?  

Schon 50% Kursanstieg heute Da haben wir nicht zu viel versproche­n :-)
Die alten Ziele sollten sehr sehr schnell erreicht werden - bei mir waren es 40,--!!!
Durch die Fusion könnten wir dieses Jahr mit etwas Glück dreistelli­g werden, den als wir die Kursziele festlegten­ dachte keine an eine Fusion - Wow!  

Zu #219 - siehe 218....  

Extrem geil! :-)  

Bin vom Fach: sehe hier ein grosses Potential  

na dann ist ja gut. :-) Sorry, ich bin nicht vom Fach, aber etwas deutlicher­e Hinweise wären gar nicht verkehrt.  

Wieviel synergien werden dabei Freigesetzt und in welcher Deadline?